Clinical Trial Underway of Drug to Prevent Skeletal-Related Events in Myeloma

The drug denosumab is approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors, but its effects in patients with multiple myeloma need to be further studied. The drug is a fully human monoclonal antibody against RANK ligand, a protein critical for osteoclast formation, maturation, and function. An international clinical trial of denosumab is underway to help determine if it can prevent skeletal-related events in myeloma.
Source: International Myeloma Foundation - Category: Hematology Source Type: news